Antimicrobial Resistance Collaborators. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet 399, 629–655 (2022).
Levy, S. B. The Antibiotic Paradox: How Miracle Drugs Are Destroying the Miracle https://doi.org/10.1007/978-1-4899-6042-9 (Springer, 1992).
Silver, L. L. Challenges of antibacterial discovery. Clin. Microbiol. Rev. 24, 71–109 https://doi.org/10.1128/cmr.00030-10 (2011).
Naghavi, M. et al. Global burden of bacterial antimicrobial resistance 1990–2021: a systematic analysis with forecasts to 2050. Lancet 404, 1199–1226 (2024).
McDonnell, A. et al. Forecasting the Fallout From AMR: Economic Impacts of Antimicrobial Resistance in Humans. A Report From the EcoAMR Series https://doi.org/10.20506/ecoAMR.3539 (WOAH & World Bank, 2024).
Walsh, C. Where will new antibiotics come from? Nat. Rev. Microbiol. 1, 65–70 (2003).
Stover, C. K. et al. A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis. Nature 405, 962–966 (2000).
Eyal, Z. et al. A novel pleuromutilin antibacterial compound, its binding mode and selectivity mechanism. Sci. Rep. 6, 39004 (2016).
Miller, A. A. et al. Discovery and characterization of QPT-1, the progenitor of a new class of bacterial topoisomerase inhibitors. Antimicrob. Agents Chemother. 52, 2806–2812 (2008).
Bax, B. D. et al. Type IIA topoisomerase inhibition by a new class of antibacterial agents. Nature 466, 935–940 (2010).
Yao, L. et al. Stepwise evolution and clonal enrichment of gepotidacin resistance in Neisseria gonorrhoeae. Antimicrob. Agents Chemother. 70, e01706-25 (2026).
Mukherjee, A. et al. Genetic background modulates zoliflodacin and gepotidacin cross-resistance and fitness in Neisseria gonorrhoeae. J. Infect. Dis. 234, e131–e140 (2026).
Wan, F., Wong, F., Collins, J. J. & de la Fuente-Nunez, C. Machine learning for antimicrobial peptide identification and design. Nat. Rev. Bioeng. 2, 392–407 (2024).
Martins, H. G. W., Gorski, D., Mussa, B., Lazo, R. E. L. & Pontarolo, R. Artificial intelligence in drug discovery for fungal diseases: a scoping review. Artif. Intell. Med. 179, 103461 (2026).
Fu, C. et al. Leveraging machine learning essentiality predictions and chemogenomic interactions to identify antifungal targets. Nat. Commun. 12, 6497 (2021).
Wensing, L. F. et al. Pooled CRISPRi screening reveals fungal-specific drug target candidates. Nat. Microbiol. 11, 2157–2169 (2026).
Behsaz, B. et al. Large-scale discovery platform enables identification of peptides targeting drug-resistant candidiasis. Cell Rep. Methods 6, 101510 https://doi.org/10.1016/j.crmeth.2026.101510 (2026).
Pitt, W. R. et al. Real-world applications and experiences of AI/ML deployment for drug discovery. J. Med. Chem. 68, 851–859 (2025).
Bender, A. et al. Artificial intelligence in drug discovery—what it is, where we stand and the path forward. Nat. Rev. Drug Discov. 25, 855–876 https://doi.org/10.1038/s41573-026-01496-2 (2026).
Hutchings, M. I., Truman, A. W. & Wilkinson, B. Antibiotics: past, present and future. Curr. Opin. Microbiol. 51, 72–80 (2019).
Moloney, M. G. Natural products as a source for novel antibiotics. Trends Pharmacol. Sci. 37, 689–701 (2016).
Atanasov, A. G., Zotchev, S. B., Dirsch, V. M. & Supuran, C. T. Natural products in drug discovery: advances and opportunities. Nat. Rev. Drug Discov. 20, 200–216 (2021).
Martínez, J. L. Antibiotics and antibiotic resistance genes in natural environments. Science 321, 365–367 (2008).
Genilloud, O. Natural products discovery and potential for new antibiotics. Curr. Opin. Microbiol. 51, 81–87 (2019).
Okada, B. K. & Seyedsayamdost, M. R. Antibiotic dialogues: induction of silent biosynthetic gene clusters by exogenous small molecules. FEMS Microbiol. Rev. 41, 19–33 (2017).
Handelsman, J., Rondon, M. R., Brady, S. F., Clardy, J. & Goodman, R. M. Molecular biological access to the chemistry of unknown soil microbes: a new frontier for natural products. Chem. Biol. 5, R245–R249 (1998).
Hover, B. M. et al. Culture-independent discovery of the malacidins as calcium-dependent antibiotics with activity against multidrug-resistant Gram-positive pathogens. Nat. Microbiol. 3, 415–422 (2018).
Wang, Z., Koirala, B., Hernandez, Y., Zimmerman, M. & Brady, S. F. Bioinformatic prospecting and synthesis of a bifunctional lipopeptide antibiotic that evades resistance. Science 376, 991–996 (2022).
Wang, Z. et al. A naturally inspired antibiotic to target multidrug-resistant pathogens. Nature 601, 606–611 (2022).
Hannigan, G. D. et al. A deep learning genome-mining strategy for biosynthetic gene cluster prediction. Nucleic Acids Res. 47, e110 (2019).
Glassey, E., Zhang, Z., King, A. M., Niquille, D. L. & Voigt, C. A. De novo design of ribosomally synthesized and post-translationally modified peptides. Nat. Chem. 17, 233–245 (2025).
Modaresi, S. M. et al. Antibiotics that kill Gram-negative bacteria by restructuring the outer membrane protein BamA. Preprint at bioRxiv https://doi.org/10.1101/2024.12.16.628070 (2024).
Morrison, K. C. & Hergenrother, P. J. Natural products as starting points for the synthesis of complex and diverse compounds. Nat. Prod. Rep. 31, 6–14 (2013).
Nicolaou, K. C. & Rigol, S. A brief history of antibiotics and select advances in their synthesis. J. Antibiot. 71, 153–184 (2018).
Liu, R., Li, X. & Lam, K. S. Combinatorial chemistry in drug discovery. Curr. Opin. Chem. Biol. 38, 117–126 (2017).
Macarron, R. et al. Impact of high-throughput screening in biomedical research. Nat. Rev. Drug Discov. 10, 188–195 (2011).
Grygorenko, O. O. et al. Generating multibillion chemical space of readily accessible screening compounds. iScience 23, 101681 (2020).
Korn, M., Ehrt, C., Ruggiu, F., Gastreich, M. & Rarey, M. Navigating large chemical spaces in early-phase drug discovery. Curr. Opin. Struct. Biol. 80, 102578 (2023).
Sadybekov, A. V. & Katritch, V. Computational approaches streamlining drug discovery. Nature 616, 673–685 (2023).
Heid, E. et al. Chemprop: a machine learning package for chemical property prediction. J. Chem. Inf. Model. 64, 9–17 (2024).
Burns, J. W. et al. Deep learning foundation models for low-data regimes from classical molecular descriptors. J. Chem. Inf. Model. 66, 10692–10701 (2026).
Krenn, M., Häse, F., Nigam, A., Friederich, P. & Aspuru-Guzik, A. Self-referencing embedded strings (SELFIES): a 100% robust molecular string representation. Mach. Learn. Sci. Technol. 1, 045024 (2020).
Vaswani, A. et al. Attention is all you need. In Advances in Neural Information Processing Systems 30 (eds Guyon, I. et al.) 6000–6010 (Curran Associates, 2017).
Chithrananda, S., Grand, G. & Ramsundar, B. ChemBERTa: large-scale self-supervised pretraining for molecular property prediction. Preprint at https://doi.org/10.48550/arXiv.2010.09885 (2020).
Ross, J. et al. Large-scale chemical language representations capture molecular structure and properties. Nat. Mach. Intell. 4, 1256–1264 (2022).
Zhou, G., Janarthanan, S., Lu, Y. & Hu, P. CL-MFAP: a contrastive learning-based multimodal foundation model for molecular property prediction and antibiotic screening. In Proc. 13th International Conference on Learning Representations (eds Yue, Y. et al.) 62386–62406 (ICLR, 2025).
Nguyen, E., Hong, Y., Toshniwal, H., Liu, Y. & Luttens, A. GLACIER: a multimodal student–teacher foundation model for molecular property prediction. In Proc. 32nd ACM SIGKDD Conf. Knowledge Discovery and Data Mining V.2 (eds Kim, W. et al.) 11705–11716 https://doi.org/10.1145/3770855.3819032 (Association for Computing Machinery, 2026).
Stokes, J. M. et al. A deep learning approach to antibiotic discovery. Cell 180, 688–702.e13 (2020).
Liu, G. et al. Deep learning-guided discovery of an antibiotic targeting Acinetobacter baumannii. Nat. Chem. Biol. 19, 1342–1350 (2023).
Anahtar, M. N. et al. Deep learning-enabled discovery of antibiotics effective against Neisseria gonorrhoeae. Sci. Transl. Med. 18, eads4699 https://doi.org/10.1126/scitranslmed.ads4699 (2026).
Zheng, E. J. et al. Discovery of antibiotics that selectively kill metabolically dormant bacteria. Cell Chem. Biol. 31, 712–728.e9 (2024).
Scalia, G. et al. Deep-learning-based virtual screening of antibacterial compounds. Nat. Biotechnol. 44, 1154–1167 https://doi.org/10.1038/s41587-025-02814-6 (2025).
Wong, F. et al. Discovery of a structural class of antibiotics with explainable deep learning. Nature 626, 177–185 (2024).
Avis, T., Wilson, F. X., Khan, N., Mason, C. S. & Powell, D. J. Targeted microbiome-sparing antibiotics. Drug Discov. Today 26, 2198–2203 (2021).
Lavecchia, A. Deep learning in drug discovery: opportunities, challenges and future prospects. Drug Discov. Today 24, 2017–2032 (2019).
Buterez, D., Janet, J. P., Kiddle, S. J., Oglic, D. & Lió, P. Transfer learning with graph neural networks for improved molecular property prediction in the multi-fidelity setting. Nat. Commun. 15, 1517 (2024).
Janarthanan, S., Zhou, G., Li, Y. Y., Jing, Z. & Hu, P. Leveraging transfer learning and multimodal foundation models for antibiotic discovery against data-scarce Escherichia coli strains. In ICLR 2025 Workshops: LMRL (ICLR, 2025).
Simm, J. et al. Splitting chemical structure data sets for federated privacy-preserving machine learning. J. Cheminform. 13, 96 (2021).
Jiménez-Luna, J., Grisoni, F. & Schneider, G. Drug discovery with explainable artificial intelligence. Nat. Mach. Intell. 2, 573–584 (2020).
Huynh, D. L. et al. AI agents in drug discovery: applications and case studies. Drug Discov. Today 31, 104650 (2026).
Wei, Z. et al. Fleming: an AI agent for antibiotic discovery in Mycobacterium tuberculosis. Preprint at bioRxiv https://doi.org/10.1101/2025.04.01.646719 (2025).
Moffat, J. G., Vincent, F., Lee, J. A., Eder, J. & Prunotto, M. Opportunities and challenges in phenotypic drug discovery: an industry perspective. Nat. Rev. Drug Discov. 16, 531–543 (2017).
Mateus, A. et al. Thermal proteome profiling in bacteria: probing protein state in vivo. Mol. Syst. Biol. 14, e8242 (2018).
Choe, D. et al. Rapid identification of key antibiotic resistance genes in E. coli using high-resolution genome-scale CRISPRi screening. iScience 28, 112435 (2025).
Briffotaux, J., Liu, S. & Gicquel, B. Genome-wide transcriptional responses of Mycobacterium to antibiotics. Front. Microbiol. 10, 249 (2019).
Zampieri, M. et al. High-throughput metabolomic analysis predicts mode of action of uncharacterized antimicrobial compounds. Sci. Transl. Med. 10, eaal3973 (2018).
Nonejuie, P., Burkart, M., Pogliano, K. & Pogliano, J. Bacterial cytological profiling rapidly identifies the cellular pathways targeted by antibacterial molecules. Proc. Natl Acad. Sci. USA 110, 16169–16174 (2013).
McQuin, C. et al. CellProfiler 3.0: next-generation image processing for biology. PLoS Biol. 16, e2005970 (2018).
Gardner, T. S., di Bernardo, D., Lorenz, D. & Collins, J. J. Inferring genetic networks and identifying compound mode of action via expression profiling. Science 301, 102–105 (2003).
Yang, J. H. et al. A white-box machine learning approach for revealing antibiotic mechanisms of action. Cell 177, 1649–1661.e9 (2019).
Smith, T. C. et al. Morphological profiling of tubercle bacilli identifies drug pathways of action. Proc. Natl Acad. Sci. USA 117, 18744–18753 (2020).
Quach, D. et al. Deep learning-driven bacterial cytological profiling to determine antimicrobial mechanisms in Mycobacterium tuberculosis. Proc. Natl Acad. Sci. USA 122, e2419813122 (2025).
Bond, A. N. et al. Reference-based chemical-genetic interaction profiling to elucidate small molecule mechanism of action in Mycobacterium tuberculosis. Nat. Commun. 16, 9673 (2025).
Swinney, D. C. Phenotypic vs. target-based drug discovery for first-in-class medicines. Clin. Pharmacol. Ther. 93, 299–301 https://doi.org/10.1038/clpt.2012.236 (2013).
Gironda-Martínez, A., Donckele, E. J., Samain, F. & Neri, D. DNA-encoded chemical libraries: a comprehensive review with successful stories and future challenges. ACS Pharmacol. Transl. Sci. 4, 1265–1279 (2021).
McCloskey, K. et al. Machine learning on DNA-encoded libraries: a new paradigm for hit finding. J. Med. Chem. 63, 8857–8866 (2020).
Anderson, A. C. The process of structure-based drug design. Chem. Biol. 10, 787–797 (2003).
Larsen, A. S., Rekis, T. & Madsen, A. Ø PhAI: a deep-learning approach to solve the crystallographic phase problem. Science 385, 522–528 (2024).
Qu, X. et al. Accelerated nuclear magnetic resonance spectroscopy with deep learning. Angew. Chem. Int. Ed. 59, 10297–10300 (2020).
Giri, N., Roy, R. S. & Cheng, J. Deep learning for reconstructing protein structures from cryo-EM density maps: recent advances and future directions. Curr. Opin. Struct. Biol. 79, 102536 (2023).
Carlsson, J. & Luttens, A. Structure-based virtual screening of vast chemical space as a starting point for drug discovery. Curr. Opin. Struct. Biol. 87, 102829 (2024).
Bender, B. J. et al. A practical guide to large-scale docking. Nat. Protoc. 16, 4799–4832 (2021).
Yang, Y. et al. Efficient exploration of chemical space with docking and deep learning. J. Chem. Theory Comput. 17, 7106–7119 (2021).
Gentile, F. et al. Deep docking: a deep learning platform for augmentation of structure based drug discovery. ACS Cent. Sci. 6, 939–949 (2020).
Luttens, A. et al. Rapid traversal of vast chemical space using machine learning-guided docking screens. Nat. Comput. Sci. 5, 301–312 (2025).
Jumper, J. et al. Highly accurate protein structure prediction with AlphaFold. Nature 596, 583–589 (2021).
Krishna, R. et al. Generalized biomolecular modeling and design with RoseTTAFold All-Atom. Science 384, eadl2528 (2024).
Passaro, S. et al. Boltz-2: towards accurate and efficient binding affinity prediction. Preprint at bioRxiv https://doi.org/10.1101/2025.06.14.659707 (2025).
Wong, F. et al. Benchmarking AlphaFold-enabled molecular docking predictions for antibiotic discovery. Mol. Syst. Biol. 18, e11081 (2022).
Lyu, J. et al. AlphaFold2 structures guide prospective ligand discovery. Science 384, eadn6354 (2024).
Díaz-Holguín, A. et al. AlphaFold accelerated discovery of psychotropic agonists targeting the trace amine-associated receptor 1. Sci. Adv. 10, eadn1524 (2024).
Peng, X. et al. Unified modeling of 3D molecular generation via atomic interactions with PocketXMol. Cell 189, 1904–1922 (2026).
Aggarwal, R., Gupta, A., Chelur, V., Jawahar, C. V. & Priyakumar, U. D. DeepPocket: ligand binding site detection and segmentation using 3D convolutional neural networks. J. Chem. Inf. Model. 62, 5069–5079 (2022).
He, W. et al. A broad-spectrum antibiotic targets multiple-drug-resistant bacteria with dual binding targets and no detectable resistance. Nat. Commun. 16, 7048 (2025).
Martin, J. K. et al. A dual-mechanism antibiotic kills Gram-negative bacteria and avoids drug resistance. Cell 181, 1518–1532.e14 (2020).
Blair, J. M. A., Webber, M. A., Baylay, A. J., Ogbolu, D. O. & Piddock, L. J. V. Molecular mechanisms of antibiotic resistance. Nat. Rev. Microbiol. 13, 42–51 (2015).
Blair, J. M., Richmond, G. E. & Piddock, L. J. Multidrug efflux pumps in Gram-negative bacteria and their role in antibiotic resistance. Future Microbiol. 9, 1165–1177 (2014).
Motika, S. E. et al. Gram-negative antibiotic active through inhibition of an essential riboswitch. J. Am. Chem. Soc. 142, 10856–10862 (2020).
Shen, T. et al. Accurate RNA 3D structure prediction using a language model-based deep learning approach. Nat. Methods 21, 2287–2298 (2024).
Wong, F. et al. Deep generative design of RNA aptamers using structural predictions. Nat. Comput. Sci. 4, 829–839 (2024).
Carvajal-Patiño, J. G. et al. RNAmigos2: accelerated structure-based RNA virtual screening with deep graph learning. Nat. Commun. 16, 2799 (2025).
Bohacek, R. S., McMartin, C. & Guida, W. C. The art and practice of structure-based drug design: a molecular modeling perspective. Med. Res. Rev. 16, 3–50 (1996).
Tingle, B. I. et al. ZINC-22—a free multi-billion-scale database of tangible compounds for ligand discovery. J. Chem. Inf. Model. https://doi.org/10.1021/acs.jcim.2c01253 (2023).
Gangwal, A. & Lavecchia, A. Unleashing the power of generative AI in drug discovery. Drug Discov. Today 29, 103992 (2024).
Lipinski, C. A., Lombardo, F., Dominy, B. W. & Feeney, P. J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 23, 3–25 (1997).
Swanson, K. et al. SyntheMol-RL: a flexible reinforcement learning framework for designing easily synthesizable antibiotics. Mol. Syst. Biol. 22, 833–867 (2026).
Swanson, K. et al. Generative AI for designing and validating easily synthesizable and structurally novel antibiotics. Nat. Mach. Intell. 6, 338–353 (2024).
Seo, S. et al. Generative flows on synthetic pathway for drug design. In Proc. 13th International Conference on Learning Representations (eds Yue, Y. et al.) 14029–14060 (ICLR, 2025).
Klarich, K., Goldman, B., Kramer, T., Riley, P. & Walters, W. P. Thompson sampling—an efficient method for searching ultralarge synthesis on demand databases. J. Chem. Inf. Model. 64, 1158–1171 https://doi.org/10.1021/acs.jcim.3c01790 (2024).
Gao, W., Luo, S. & Coley, C. W. Generative AI for navigating synthesizable chemical space. Proc. Natl Acad. Sci. USA 122, e2415665122 (2025).
Wang, Y. et al. A generative artificial intelligence approach for the discovery of antimicrobial peptides against multidrug-resistant bacteria. Nat. Microbiol. 10, 2997–3012 (2025).
Szymczak, P. et al. Discovering highly potent antimicrobial peptides with deep generative model HydrAMP. Nat. Commun. 14, 1453 (2023).
Watson, J. L. et al. De novo design of protein structure and function with RFdiffusion. Nature 620, 1089–1100 (2023).
Torres, M. D. T., Chen, L. T., Wan, F., Chatterjee, P. & de la Fuente-Nunez, C. Generative latent diffusion language modeling yields anti-infective synthetic peptides. Cell Biomater. 1, 100183 (2025).
Torres, M. D. T. et al. A generative artificial intelligence approach for peptide antibiotic optimization. Nat. Mach. Intell. 8, 841–856 (2026).
Polishchuk, P. CReM: chemically reasonable mutations framework for structure generation. J. Cheminform. 12, 28 (2020).
Jin, W., Barzilay, R. & Jaakkola, T. Junction tree variational autoencoder for molecular graph generation. In Proc. 35th International Conference on Machine Learning (eds Dy, J. & Krause, A.) 2323–2332 (PMLR, 2018).
Krishnan, A. et al. A generative deep learning approach to de novo antibiotic design. Cell 188, 5962–5979.e22 (2025).
Gao, W. & Coley, C. W. The synthesizability of molecules proposed by generative models. J. Chem. Inf. Model. 60, 5714–5723 (2020).
Ertl, P. & Schuffenhauer, A. Estimation of synthetic accessibility score of drug-like molecules based on molecular complexity and fragment contributions. J. Cheminform. 1, 8 (2009).
Thakkar, A., Chadimová, V., Bjerrum, E. J., Engkvist, O. & Reymond, J.-L. Retrosynthetic accessibility score (RAscore)—rapid machine learned synthesizability classification from AI driven retrosynthetic planning. Chem. Sci. 12, 3339–3349 (2021).
Tu, Z. et al. ASKCOS: open-source, data-driven synthesis planning. Acc. Chem. Res. 58, 1764–1775 (2025).
Fromer, J. C. & Coley, C. W. An algorithmic framework for synthetic cost-aware decision making in molecular design. Nat. Comput. Sci. 4, 440–450 (2024).
Dekleva, D. et al. Synthesizability via reward engineering: expanding generative molecular design into synthetic space. Chem. Sci. 17, 10015–10028 (2026).
Sundin, I. et al. Human-in-the-loop assisted de novo molecular design. J. Cheminform. 14, 86 (2022).
Lipinski, C. A. Drug-like properties and the causes of poor solubility and poor permeability. J. Pharmacol. Toxicol. Methods 44, 235–249 (2000).
Swanson, K. et al. ADMET-AI: a machine learning ADMET platform for evaluation of large-scale chemical libraries. Bioinformatics 40, btae416 (2024).
Kola, I. & Landis, J. Can the pharmaceutical industry reduce attrition rates? Nat. Rev. Drug Discov. 3, 711–716 (2004).
Lipinski, C. A. Lead- and drug-like compounds: the rule-of-five revolution. Drug. Discov. Today Technol. 1, 337–341 (2004).
Fraser, J. S. et al. Mapping the avoid-ome: a systematic open-science approach to predictive ADMET. Nat. Commun. 17, 4644 (2026).
Huang, K. et al. Therapeutics Data Commons: machine learning datasets and tasks for drug discovery and development. In Proc. 35th Neural Information Processing Systems Track on Datasets and Benchmarks 1 121 (NeurIPS, 2021).
Fralish, Z., Chen, A., Skaluba, P. & Reker, D. DeepDelta: predicting ADMET improvements of molecular derivatives with deep learning. J. Cheminform. 15, 101 (2023).
Masi, M., Réfregiers, M., Pos, K. M. & Pagès, J.-M. Mechanisms of envelope permeability and antibiotic influx and efflux in Gram-negative bacteria. Nat. Microbiol. 2, 17001 (2017).
Zgurskaya, H. I., López, C. A. & Gnanakaran, S. Permeability barrier of Gram-negative cell envelopes and approaches to bypass it. ACS Infect. Dis. 1, 512–522 https://doi.org/10.1021/acsinfecdis.5b00097 (2015).
Du, D. et al. Multidrug efflux pumps: structure, function and regulation. Nat. Rev. Microbiol. 16, 523–539 (2018).
Muñoz, K. A. & Hergenrother, P. J. Facilitating compound entry as a means to discover antibiotics for Gram-negative bacteria. Acc. Chem. Res. 54, 1322–1333 (2021).
Plé, C. et al. Pyridylpiperazine-based allosteric inhibitors of RND-type multidrug efflux pumps. Nat. Commun. 13, 115 (2022).
Gurvic, D. & Zachariae, U. Multidrug efflux in Gram-negative bacteria: structural modifications in active compounds leading to efflux pump avoidance. npj Antimicrob. Resist. 2, 6 (2024).
Lepori, I. et al. Identification of chemical features for improved outer membrane permeation in mycobacteria using machine learning. Nat. Microbiol. 11, 2647–2665 https://doi.org/10.1038/s41564-026-02412-5 (2026).
Rayner, B., Verderosa, A. D., Ferro, V. & Blaskovich, M. A. T. Siderophore conjugates to combat antibiotic-resistant bacteria. RSC Med. Chem. 14, 800–822 (2023).
Pelgrift, R. Y. & Friedman, A. J. Nanotechnology as a therapeutic tool to combat microbial resistance. Adv. Drug Deliv. Rev. 65, 1803–1815 (2013).
Paul-Satyaseela, M. Invention of enmetazobactam: an Indian triumph in antimicrobial drug discovery. ACS Infect. Dis. 11, 1–3 (2025).
Durand-Réville, T. F. et al. ETX2514 is a broad-spectrum β-lactamase inhibitor for the treatment of drug-resistant Gram-negative bacteria including Acinetobacter baumannii. Nat. Microbiol. 2, 17104 (2017).
Isoda, T. et al. Syntheses and pharmacokinetic studies of prodrug esters for the development of oral carbapenem, L-084. J. Antibiot. 59, 241–247 (2006).
Novak, R. & Shlaes, D. M. The pleuromutilin antibiotics: a new class for human use. Curr. Opin. Investig. Drugs 11, 182–191 (2010).
Ito, A. et al. Siderophore cephalosporin cefiderocol utilizes ferric iron transporter systems for antibacterial activity against Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 60, 7396–7401 (2016).
Xu, F., Sherry, B. D. & Blizzard, T. A. Discovery and chemical development of relebactam: a potent β-lactamase inhibitor in combination with Primaxin for the treatment of serious and antibiotic-resistant bacterial infections. In Complete Accounts of Integrated Drug Discovery and Development: Recent Examples from the Pharmaceutical Industry Volume 3 (eds Pesti, J. A. et al.) 253–284 (American Chemical Society, 2020).
Aggen, J. B. et al. Synthesis and spectrum of the neoglycoside ACHN-490. Antimicrob. Agents Chemother. 54, 4636–4642 https://doi.org/10.1128/aac.00572-10 (2010).
Liu, F. & Myers, A. G. Development of a platform for the discovery and practical synthesis of new tetracycline antibiotics. Curr. Opin. Chem. Biol. 32, 48–57 (2016).
Moore, A. Y., Rosso, J. D., Johnson, J. L. & Grada, A. Sarecycline: a review of preclinical and clinical evidence. Clin. Cosmet. Investig. Dermatol. 13, 553–560 (2020).
Honeyman, L. et al. Structure–activity relationship of the aminomethylcyclines and the discovery of omadacycline. Antimicrob. Agents Chemother. 54, 7044–7053 https://doi.org/10.1128/aac.01536-15 (2015).
Coleman, K. Diazabicyclooctanes (DBOs): a potent new class of non-β-lactam β-lactamase inhibitors. Curr. Opin. Microbiol. 14, 550–555 (2011).
Minamimura, M., Taniyama, Y., Inoue, R. & Mitsuhashi, S. In vitro antibacterial activity and β-lactamase stability of CP-70,429 a new penem antibiotic. Antimicrob. Agents Chemother. 37, 1547–1551 https://doi.org/10.1128/aac.37.7.1547 (1993).
Yao, R. et al. Sudapyridine (WX-081), a novel compound against Mycobacterium tuberculosis. Microbiol. Spectr. 10, e02477-21 (2022).
Hariguchi, N. et al. OPC-167832, a novel carbostyril derivative with potent antituberculosis activity as a DprE1 Inhibitor. Antimicrob. Agents Chemother. 64, e02020-19 https://doi.org/10.1128/aac.02020-19 (2020).
Pethe, K. et al. Discovery of Q203, a potent clinical candidate for the treatment of tuberculosis. Nat. Med. 19, 1157–1160 (2013).
Suckling, C. J. The antibacterial drug MGB-BP3: from discovery to clinical trial. Chem. Biol. Interface 5, 166–174 (2015).
Li, X. et al. Discovery of a potent and specific M. tuberculosis leucyl-tRNA synthetase inhibitor: (S)-3-(aminomethyl)-4-chloro-7-(2-hydroxyethoxy)benzo[c][1,2]oxaborol-1(3H)-ol (GSK656). J. Med. Chem. 60, 8011–8026 (2017).
Brown, P. et al. Design of next generation polymyxins with lower toxicity: the discovery of SPR206. ACS Infect. Dis. 5, 1645–1656 (2019).
Robertson, G. T. et al. In vitro evaluation of CBR-2092, a novel rifamycin–quinolone hybrid antibiotic: studies of the mode of action in Staphylococcus aureus. Antimicrob. Agents Chemother. 52, 2313–2323 https://doi.org/10.1128/aac.01649-07 (2008).
Willand, N. et al. Synthetic EthR inhibitors boost antituberculous activity of ethionamide. Nat. Med. 15, 537–544 (2009).
Han, Z. et al. Structure-based drug design and optimization of mannoside bacterial FimH antagonists. J. Med. Chem. 53, 4779–4792 (2010).
Kaul, M. et al. TXA709, an FtsZ-targeting benzamide prodrug with improved pharmacokinetics and enhanced in vivo efficacy against methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 59, 4845–4855 https://doi.org/10.1128/aac.00708-15 (2015).
Payne, D. J. et al. Discovery of a novel and potent class of FabI-directed antibacterial agents. Antimicrob. Agents Chemother. 46, 3118–3124 https://doi.org/10.1128/aac.46.10.3118-3124.2002 (2002).
Slingerland, C. J. et al. Synthesis and evaluation of polymyxins bearing reductively labile disulfide-linked lipids. J. Med. Chem. 65, 15878–15892 (2022).
Zampaloni, C. et al. A novel antibiotic class targeting the lipopolysaccharide transporter. Nature 625, 566–571 (2024).
Source: www.nature.com



